Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Surgery
Erschienen in: Journal of Gastrointestinal Surgery 5/2011

01.05.2011 | Review Article

Barrett’s Esophagus: A Review of the Literature

verfasst von: Erin W. Gilbert, Renato A. Luna, Vincent L. Harrison, John G. Hunter

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Barrett’s esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia of the tubular esophagus that results from chronic gastroesophageal reflux. Which patients are at risk of having BE and which are at further risk of developing EAC has yet to be fully established. Many aspects of the management of BE have changed considerably in the past 5 years alone. The aim of this review is to define the critical elements necessary to effectively manage individuals with BE. The general prevalence of BE is estimated at 1.6–3% and follows a demographic distribution similar to EAC. Both short-segment (<3 cm) and long-segment (≥3 cm) BE confer a significant risk for EAC that is increased by the development of dysplasia. The treatment for flat high-grade dysplasia is endoscopic radiofrequency ablation therapy. The benefits of ablation for non-dysplastic BE and BE with low-grade dysplasia have yet to be validated. By understanding the intricacies of the development, screening, surveillance, and treatment of BE, new insights will be gained into the prevention and early detection of EAC that may ultimately lead to a reduction in morbidity and mortality in this patient population.
Literatur
1.
2.
N. R. Barrett, "Chronic peptic ulcer of the oesophagus and 'oesophagitis'." Br. J. Surg., vol. 38, pp. 175–182, Oct, 1950.PubMedCrossRef
3.
4.
K. K. Wang, R. E. Sampliner and Practice Parameters Committee of the American College of,Gastroenterology, “Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.” Am. J. Gastroenterol., vol. 103, pp. 788–797, Mar, 2008.PubMedCrossRef
5.
A. J. Cameron, A. R. Zinsmeister, D. J. Ballard and J. A. Carney, “Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings.” Gastroenterology, vol. 99, pp. 918–922, Oct, 1990.PubMed
6.
J. Ronkainen, P. Aro, T. Storskrubb, S. E. Johansson, T. Lind, E. Bolling-Sternevald, M. Vieth, M. Stolte, N. J. Talley and L. Agreus, “Prevalence of Barrett’s esophagus in the general population: an endoscopic study.” Gastroenterology, vol. 129, pp. 1825–1831, Dec, 2005.PubMedCrossRef
7.
8.
M. A. Eloubeidi and D. Provenzale, “Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans.” J. Clin. Gastroenterol., vol. 33, pp. 306–309, Oct, 2001.PubMedCrossRef
9.
R. V. Lord, K. Wickramasinghe, J. J. Johansson, S. R. Demeester, J. Brabender and T. R. Demeester, “Cardiac mucosa in the remnant esophagus after esophagectomy is an acquired epithelium with Barrett’s-like features.” Surgery, vol. 136, pp. 633–640, Sep, 2004.PubMedCrossRef
10.
A. C. Ford, D. Forman, P. D. Reynolds, B. T. Cooper and P. Moayyedi, “Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus.” Am. J. Epidemiol., vol. 162, pp. 454–460, Sep 1, 2005.PubMedCrossRef
11.
Z. R. Edelstein, D. C. Farrow, M. P. Bronner, S. N. Rosen and T. L. Vaughan, “Central adiposity and risk of Barrett’s esophagus.” Gastroenterology, vol. 133, pp. 403–411, Aug, 2007.PubMedCrossRef
12.
13.
V. N. Shirvani, R. Ouatu-Lascar, B. S. Kaur, M. B. Omary and G. Triadafilopoulos, “Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.” Gastroenterology, vol. 118, pp. 487–496, Mar, 2000.PubMedCrossRef
14.
D. Das, A. P. Chilton and J. A. Jankowski, “Chemoprevention of oesophageal cancer and the AspECT trial,” Recent Results Cancer Res., vol. 181, pp. 161–169, 2009.PubMedCrossRef
15.
16.
17.
P. Sharma, G. W. Falk, A. P. Weston, D. Reker, M. Johnston and R. E. Sampliner, “Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus.” Clin. Gastroenterol. Hepatol., vol. 4, pp. 566–572, May, 2006.PubMedCrossRef
18.
Conio M. Blanchi S. Lapertosa G. Ferraris R. Sablich R. Marchi S. D’Onofrio V. Lacchin T. Iaquinto G. Missale G. Ravelli P. Cestari R. Benedetti G. Macrì G. Fiocca R. Munizzi F. Filiberti R, “Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.” Am. J. Gastroenterol., vol. 98, pp. 1931–1939, Sep, 2003.PubMedCrossRef
19.
20.
A. P. Weston, P. Sharma, S. Mathur, S. Banerjee, A. K. Jafri, R. Cherian, D. McGregor, R. S. Hassanein and M. Hall, “Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis.” Am. J. Gastroenterol., vol. 99, pp. 1657–1666, Sep, 2004.PubMedCrossRef
21.
22.
R. E. Rudolph, T. L. Vaughan, B. E. Storer, R. C. Haggitt, P. S. Rabinovitch, D. S. Levine and B. J. Reid, “Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.” Ann. Intern. Med., vol. 132, pp. 612–620, Apr 18, 2000.PubMed
23.
P. T. Chandrasoma, R. Der, P. Dalton, G. Kobayashi, Y. Ma, J. Peters and T. Demeester, “Distribution and significance of epithelial types in columnar-lined esophagus.” Am. J. Surg. Pathol., vol. 25, pp. 1188–1193, Sep, 2001.PubMedCrossRef
24.
P. T. Chandrasoma, R. Der, Y. Ma, P. Dalton and M. Taira, “Histology of the gastroesophageal junction: an autopsy study.” Am. J. Surg. Pathol., vol. 24, pp. 402–409, Mar, 2000.PubMedCrossRef
25.
26.
27.
F. Paraf, J. F. Flejou, J. P. Pignon, F. Fekete and F. Potet, “Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases.” Am. J. Surg. Pathol., vol. 19, pp. 183–191, Feb, 1995.PubMedCrossRef
28.
R. J. Schlemper, R. H. Riddell, Y. Kato, F. Borchard, H. S. Cooper, S. M. Dawsey, M. F. Dixon, C. M. Fenoglio-Preiser, J. F. Flejou, K. Geboes, T. Hattori, T. Hirota, M. Itabashi, M. Iwafuchi, A. Iwashita, Y. I. Kim, T. Kirchner, M. Klimpfinger, M. Koike, G. Y. Lauwers, K. J. Lewin, G. Oberhuber, F. Offner, A. B. Price, C. A. Rubio, M. Shimizu, T. Shimoda, P. Sipponen, E. Solcia, M. Stolte, H. Watanabe and H. Yamabe, “The Vienna classification of gastrointestinal epithelial neoplasia.” Gut, vol. 47, pp. 251–255, Aug, 2000.PubMedCrossRef
29.
30.
31.
32.
G. S. Dulai, P. G. Shekelle, D. M. Jensen, B. M. Spiegel, J. Chen, D. Oh and K. L. Kahn, “Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort.” Am. J. Gastroenterol., vol. 100, pp. 775–783, Apr, 2005.PubMedCrossRef
33.
M. Kerkhof, H. van Dekken, E. W. Steyerberg, G. A. Meijer, A. H. Mulder, A. de Bruine, A. Driessen, F. J. ten Kate, J. G. Kusters, E. J. Kuipers, P. D. Siersema and g. CYBAR study, “Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.” Histopathology, vol. 50, pp. 920–927, Jun, 2007.PubMedCrossRef
34.
S. B. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene and A. Tritti, Eds., AJCC Cancer Staging Manual. New York: Springer, 2009.
35.
36.
P. Sharma, J. Dent, D. Armstrong, J. J. Bergman, L. Gossner, Y. Hoshihara, J. A. Jankowski, O. Junghard, L. Lundell, G. N. Tytgat and M. Vieth, “The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria.” Gastroenterology, vol. 131, pp. 1392–1399, Nov, 2006.PubMedCrossRef
37.
R. Harrison, I. Perry, W. Haddadin, S. McDonald, R. Bryan, K. Abrams, R. Sampliner, N. J. Talley, P. Moayyedi and J. A. Jankowski, “Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies.” Am. J. Gastroenterol., vol. 102, pp. 1154–1161, Jun, 2007.PubMedCrossRef
38.
B. J. Reid, P. L. Blount, Z. Feng and D. S. Levine, “Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia.” Am. J. Gastroenterol., vol. 95, pp. 3089–3096, Nov, 2000.PubMedCrossRef
39.
A. May, E. Gunter, F. Roth, L. Gossner, M. Stolte, M. Vieth and C. Ell, “Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.” Gut, vol. 53, pp. 634–640, May, 2004.PubMedCrossRef
40.
S. Ngamruengphong, V. K. Sharma and A. Das, “Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis.” Gastrointest. Endosc., vol. 69, pp. 1021–1028, May, 2009.PubMedCrossRef
41.
42.
43.
J. M. Inadomi, R. Sampliner, J. Lagergren, D. Lieberman, A. M. Fendrick and N. Vakil, “Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.” Ann. Intern. Med., vol. 138, pp. 176–186, Feb 4, 2003.PubMed
44.
A. Chak, A. Faulx, C. Eng, W. Grady, M. Kinnard, H. Ochs-Balcom and G. Falk, “Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia.” Cancer, vol. 107, pp. 2160–2166, Nov 1, 2006.PubMedCrossRef
45.
M. Maffei and J. M. Dumonceau, “Transnasal esogastroduodenoscopy (EGD): comparison with conventional EGD and new applications,” Swiss Med. Wkly., vol. 138, pp. 658–664, Nov 15, 2008.PubMed
46.
B. A. Jobe, J. G. Hunter, E. Y. Chang, C. Y. Kim, G. M. Eisen, J. D. Robinson, B. S. Diggs, R. W. O’Rourke, A. E. Rader, P. Schipper, D. A. Sauer, J. H. Peters, D. A. Lieberman and C. D. Morris, “Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison.” Am. J. Gastroenterol., vol. 101, pp. 2693–2703, Dec, 2006.PubMedCrossRef
47.
48.
49.
R. C. Fitzgerald, I. T. Saeed, D. Khoo, M. J. Farthing and W. R. Burnham, “Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus.” Dig. Dis. Sci., vol. 46, pp. 1892–1898, Sep, 2001.PubMedCrossRef
50.
51.
N. S. Buttar, K. K. Wang, T. J. Sebo, D. M. Riehle, K. K. Krishnadath, L. S. Lutzke, M. A. Anderson, T. M. Petterson and L. J. Burgart, “Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.” Gastroenterology, vol. 120, pp. 1630–1639, Jun, 2001.PubMedCrossRef
52.
E. E. Tseng, T. T. Wu, C. J. Yeo and R. F. Heitmiller, “Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome--an update.” J. Gastrointest. Surg., vol. 7, pp. 164–170, discussion 170–1; Feb, 2003.PubMedCrossRef
53.
54.
55.
R. Ouatu-Lascar and G. Triadafilopoulos, “Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett’s esophagus.” Am. J. Gastroenterol., vol. 93, pp. 711–716, May, 1998.PubMedCrossRef
56.
R. W. Yeh, L. B. Gerson and G. Triadafilopoulos, “Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus.” Dis. Esophagus, vol. 16, pp. 193–198, 2003.PubMedCrossRef
57.
R. C. Fitzgerald, R. Lascar and G. Triadafilopoulos, “Review article: Barrett’s oesophagus, dysplasia and pharmacologic acid suppression,” Aliment. Pharmacol. Ther., vol. 15, pp. 269–276, Mar, 2001.PubMedCrossRef
58.
J. D. Horwhat, D. Baroni, C. Maydonovitch, E. Osgard, E. Ormseth, E. Rueda-Pedraza, H. J. Lee, W. K. Hirota and R. K. Wong, “Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data.” Am. J. Gastroenterol., vol. 102, pp. 497–506, Mar, 2007.PubMedCrossRef
59.
F. T. Peters, S. Ganesh, E. J. Kuipers, W. J. Sluiter, E. C. Klinkenberg-Knol, C. B. Lamers and J. H. Kleibeuker, “Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study,” Gut, vol. 45, pp. 489–494, Oct, 1999.PubMedCrossRef
60.
61.
H. B. El-Serag, T. V. Aguirre, S. Davis, M. Kuebeler, A. Bhattacharyya and R. E. Sampliner, “Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus.” Am. J. Gastroenterol., vol. 99, pp. 1877–1883, Oct, 2004.PubMedCrossRef
62.
L. Monaco, A. Brillantino, F. Torelli, M. Schettino, G. Izzo, A. Cosenza and N. Di Martino, “Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors.” World J. Gastroenterol., vol. 15, pp. 334–338, Jan 21, 2009.PubMedCrossRef
63.
C. B. Morgenthal, M. D. Shane, A. Stival, N. Gletsu, G. Milam, V. Swafford, J. G. Hunter and C. D. Smith, “The durability of laparoscopic Nissen fundoplication: 11-year outcomes.” J. Gastrointest. Surg., vol. 11, pp. 693–700, Jun, 2007.PubMedCrossRef
64.
65.
A. Ortiz, L. F. Martinez de Haro, P. Parrilla, G. Morales, J. Molina, J. Bermejo, R. Liron and J. Aguilar, “Conservative treatment versus antireflux surgery in Barrett’s oesophagus: long-term results of a prospective study.” Br. J. Surg., vol. 83, pp. 274–278, Feb, 1996.PubMedCrossRef
66.
M. Rossi, M. Barreca, N. de Bortoli, C. Renzi, S. Santi, A. Gennai, M. Bellini, F. Costa, M. Conio and S. Marchi, “Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.” Ann. Surg., vol. 243, pp. 58–63, Jan, 2006.PubMedCrossRef
67.
68.
E. Y. Chang, C. D. Morris, A. K. Seltman, R. W. O’Rourke, B. K. Chan, J. G. Hunter and B. A. Jobe, “The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review,” Ann. Surg., vol. 246, pp. 11–21, Jul, 2007.PubMedCrossRef
69.
J. Lagergren and P. Viklund, “Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux?.” World J. Surg., vol. 31, pp. 465–469, Mar, 2007.PubMedCrossRef
70.
Oberg S. Wenner J. Johansson J. Walther B. Willén R, “Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma.” Ann. Surg., vol. 242, pp. 49–54, Jul, 2005.PubMedCrossRef
71.
72.
B. J. Reid, R. C. Haggitt, C. E. Rubin, G. Roth, C. M. Surawicz, G. Van Belle, K. Lewin, W. M. Weinstein, D. A. Antonioli and H. Goldman, “Observer variation in the diagnosis of dysplasia in Barrett’s esophagus.” Hum. Pathol., vol. 19, pp. 166–178, Feb, 1988.PubMedCrossRef
73.
N. J. Shaheen, P. Sharma, B. F. Overholt, H. C. Wolfsen, R. E. Sampliner, K. K. Wang, J. A. Galanko, M. P. Bronner, J. R. Goldblum, A. E. Bennett, B. A. Jobe, G. M. Eisen, M. B. Fennerty, J. G. Hunter, D. E. Fleischer, V. K. Sharma, R. H. Hawes, B. J. Hoffman, R. I. Rothstein, S. R. Gordon, H. Mashimo, K. J. Chang, V. R. Muthusamy, S. A. Edmundowicz, S. J. Spechler, A. A. Siddiqui, R. F. Souza, A. Infantolino, G. W. Falk, M. B. Kimmey, R. D. Madanick, A. Chak and C. J. Lightdale. (2009, May 28). Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 360(22), pp. 2277–2288. Available: http://​ovidsp.​ovid.​com/​ovidweb.​cgi?​T=​JS&​CSC=​Y&​NEWS=​N&​PAGE=​fulltext&​D=​medl&​AN=​19474425.PubMedCrossRef
74.
75.
76.
H. J. Stein, M. Feith, B. L. Bruecher, J. Naehrig, M. Sarbia and J. R. Siewert, “Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.” Ann. Surg., vol. 242, pp. 566–573, discussion 573–5; Oct, 2005.PubMed
77.
H. Fujita, S. Sueyoshi, H. Yamana, K. Shinozaki, U. Toh, Y. Tanaka, T. Mine, M. Kubota, K. Shirouzu, A. Toyonaga, H. Harada, S. Ban, M. Watanabe, Y. Toda, E. Tabuchi, N. Hayabuchi and H. Inutsuka, “Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy.” World J. Surg., vol. 25, pp. 424–431, Apr, 2001.PubMedCrossRef
78.
C. G. Peyre, S. R. DeMeester, C. Rizzetto, N. Bansal, A. L. Tang, S. Ayazi, J. M. Leers, J. C. Lipham, J. A. Hagen and T. R. DeMeester, “Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia.” Ann. Surg., vol. 246, pp. 665–671, discussion 671–4; Oct, 2007.PubMedCrossRef
79.
M. Vieth, C. Ell, L. Gossner, A. May and M. Stolte, “Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia.” Endoscopy, vol. 36, pp. 776–781, Sep, 2004.PubMedCrossRef
80.
81.
H. Heinrich and P. Bauerfeind, “Endoscopic mucosal resection for staging and therapy of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third,” Recent Results Cancer Res., vol. 182, pp. 85–91, 2010.PubMedCrossRef
82.
83.
84.
D. K. Rex, O. W. Cummings, M. Shaw, M. D. Cumings, R. K. Wong, R. S. Vasudeva, D. Dunne, E. Y. Rahmani and D. J. Helper, “Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn.” Gastroenterology, vol. 125, pp. 1670–1677, Dec, 2003.PubMedCrossRef
85.
86.
L. B. Gerson, K. Shetler and G. Triadafilopoulos, “Prevalence of Barrett’s esophagus in asymptomatic individuals.” Gastroenterology, vol. 123, pp. 461–467, Aug, 2002.PubMedCrossRef
87.
88.
89.
B. Westhoff, S. Brotze, A. Weston, C. McElhinney, R. Cherian, M. S. Mayo, H. J. Smith and P. Sharma, “The frequency of Barrett’s esophagus in high-risk patients with chronic GERD.” Gastrointest. Endosc., vol. 61, pp. 226–231, Feb, 2005.PubMedCrossRef
90.
S. J. Veldhuyzen van Zanten, A. B. Thomson, A. N. Barkun, D. Armstrong, N. Chiba, R. J. White, S. Escobedo and P. Sinclair, “The prevalence of Barrett’s oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy.” Aliment. Pharmacol. Ther., vol. 23, pp. 595–599, Mar 1, 2006.PubMedCrossRef
91.
Metadaten
Titel
Barrett’s Esophagus: A Review of the Literature
verfasst von
Erin W. Gilbert
Renato A. Luna
Vincent L. Harrison
John G. Hunter
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 5/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1485-y

Weitere Artikel der Ausgabe 5/2011

Journal of Gastrointestinal Surgery 5/2011 Zur Ausgabe

Original Article

Doppler-Guided Hemorrhoidal Artery Ligation: The Experience of a Single Institution

Original Article

Reflux Esophagitis and Marginal Ulcer After Pancreaticoduodenectomy

2010 SSAT Plenary Presentation

The Duration of Symptoms Predicts the Presence of Malignancy in 210 Resected Cases of Pancreatic Intraductal Papillary Mucinous Neoplasms

Pancreas Club Meeting Proceedings

Summary of the 44th Annual Pancreas Club Meeting Proceedings

2011 SSAT Annual Meeting

An Evidence-Based Review of the Surgical Treatment of Gastric Adenocarcinoma

Original Article

Patterns of Pancreatic Resection Differ Between Patients with Familial and Sporadic Pancreatic Cancer

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.